Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury

NCT00500812 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT00500812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00500812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2005
Completion date
February 28, 2009
Enrollment
48 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

spinal cord injury